Search clinical trials for: HIV-1 Reverse Transcriptase

Total 56293 results

Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
Wellness Wheel Medical Clinic
University of Saskatchewan; Saskatchewan Health Authority - Regina Area; CIHR...

Recruiting

Syphilis and HIV Point of Care Testing (POCT) in Saskatchewan (SHIVER)

HIV Infections | Syphilis

Canada
Cepheid

Completed

Clinical Evaluation of the Xpert® HIV-1 VL

Human Immunodeficiency Virus
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States
National Institutes of Health Clinical Center (CC)

Completed

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

HIV Infection | Hepatitis C

United States
Qing XIe
Shanghai MedSci Healthcare Co. Ltd

Unknown

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

Hepatocellular Carcinoma | Hepatitis B, Chronic | Compensated Cirrhosis

China
Nanfang Hospital of Southern Medical University
JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd

Unknown

Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Hepatitis B

China
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

More Than a Machine: Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Uganda

HIV-1-infection

Uganda
Gilead Sciences

Completed

Safety Study of Once a Day ART and Opiate Substitute. (3OD)

HIV Infections

Germany
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Completed

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention (PROMISE-EPI)

HIV-1

Burkina Faso, Zambia
Hospital Universitari Vall d'Hebron Research Institute
Gilead Sciences

Completed

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

HIV-1

Spain
Gilead Sciences

Completed

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada (RECOMB)

HIV-1

Spain
University of Aarhus
Aarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...

Completed

PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (PIONA)

HIV-1

Guinea-Bissau
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Merck Sharp & Dohme LLC

Completed

A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

HIV-1
Ratiopharm GmbH

Completed

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

HIV-1

United Kingdom
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine (MERIT)

HIV-1

United States, Canada, United Kingdom, Netherlands, Argentina, Australia, Belgium, South Africa, Switzerland, Italy, Puerto Rico, Brazil, Mexico, Poland
Gilead Sciences

Completed

ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial (ROCKET II)

HIV-1

Austria, Germany, Italy, Spain
MRC/UVRI and LSHTM Uganda Research Unit
Karolinska Institutet; Amsterdam Institute for Global Health and Development; University of Rwanda and other collaborators

Recruiting

East Africa Point of Care Viral Load Study (EAPoC-VL)

HIV | Viral Load | Point of Care Monitoring

Kenya, Uganda
Sun Yat-sen University

Recruiting

A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

Hepatocellular Carcinoma Recurrent

China
Pfizer

Terminated

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

HIV-1

Spain, United Kingdom, Malaysia, United States, Portugal, Brazil, Germany, Italy, Poland, Puerto Rico, South Africa, Taiwan, Ukraine
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Juan A. Arnaiz

Completed

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

HIV-1

Spain
Korea University
GlaxoSmithKline

Completed

Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
University of Washington
University of Nairobi

Completed

Patient Actor Training to Improve HIV Services for Adolescents in Kenya (SPEED)

HIV/AIDS

Kenya
Merck Sharp & Dohme LLC

Terminated

Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (DRIVE-FORWARD)

HIV-1
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

HIV-1

United States, South Africa, Ukraine, Kenya, Thailand, India, Romania, Uganda
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

HIV Infections | HIV-1 | Human Immunodeficiency Virus Type 1

United States, Australia, France, United Kingdom, Taiwan, Spain, Argentina, Portugal, Romania, South Africa, Canada, Denmark, Sweden, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Mexico
Johns Hopkins University
Centers for Disease Control and Prevention

Recruiting

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC) (EHPOC)

HIV Infections | Syphilis

United States
Merck Sharp & Dohme LLC

Completed

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

HIV-1 | Central Nervous System
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz

Active, not recruiting

Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV (PREVENIR-PEV)

HIV-1

Burkina Faso
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

HIV Infections | HIV-1

United States, France, United Kingdom, China, Belgium, Germany, Spain, Chile, Mexico, Portugal, Costa Rica, Panama, South Africa, Canada, Brazil, Puerto Rico, Russian Federation, Thailand, Australia, India
Gilead Sciences

Completed

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

HIV Infections

United Kingdom
Gilead Sciences

Completed

An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects

HIV Infections

Romania
Pfizer
ViiV Healthcare

Terminated

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

HIV-1

South Africa, Australia, United Kingdom, Canada, Italy, Poland, Switzerland, Mexico, Brazil
Tibotec Pharmaceuticals, Ireland

Terminated

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

HIV-1
Gilead Sciences

Completed

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada (TOTEM)

HIV Infections

France
Janssen Sciences Ireland UC

Active, not recruiting

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

HIV Infections | HIV-1

United States, France, Spain, South Africa, Canada, Argentina, Thailand, Brazil, Romania, Panama, Puerto Rico
Gilead Sciences

Active, not recruiting

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

HIV-1

United States, Panama, South Africa
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation

Pharmacokinetics | Bioavailability | HIV-1
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

HIV-1 | Anti-Retroviral Agents
Valley AIDS Council
Gilead Sciences

Not yet recruiting

Advanced HIV: Outcomes for Rapid ART (AHORA)

HIV-1-infection
Professor Francois Venter

Recruiting

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance (ADORE)

HIV-1-infection

South Africa
Association de Recherche en Virologie et Dermatologie
ViiV Healthcare

Completed

Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy (MUTARESERVOIR)

HIV-1-infection

France
Professor Francois Venter

Completed

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (ADVANCE)

HIV-1 Infection

South Africa
University of Alberta
University of British Columbia; Gilead Sciences

Terminated

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

HIV-1-infection

Canada

3

Subscribe